Do analysts rate BCTX or ALDX?

Aldeyra Therapeutics has a consensus price target of $5.50, indicating a potential upside of 184.97%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aldeyra Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, BCTX or ALDX?

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Briacell Therap N/A N/A -$26.31M -$7.92 N/A Aldeyra Therapeutics N/A N/A -$33.85M -$0.46 N/A

Is BCTX or ALDX more profitable?

Aldeyra Therapeutics' return on equity of -57.34% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% Aldeyra Therapeutics N/A -57.34% -36.33%

Do analysts prefer BCTX or ENGN?

enGene has a consensus price target of $11.05, indicating a potential upside of 482.87%. Given enGene's stronger consensus rating and higher probable upside, analysts plainly believe enGene is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 enGene 2 Sell rating(s) 8 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.14

Which has stronger earnings & valuation, BCTX or ENGN?

enGene is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Briacell Therap N/A N/A -$26.31M -$7.92 N/A enGene N/A N/A -$117.30M -$2.17 N/A

Is BCTX or ENGN more profitable?

enGene's return on equity of -56.06% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% enGene N/A -56.06% -45.64%

Do analysts prefer BCTX or SPRO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts rate BCTX or PMN?

Promis Neurosciences has a consensus target price of $24.00, suggesting a potential upside of 75.70%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts clearly believe Promis Neurosciences is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Promis Neurosciences 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.86

Which has better earnings & valuation, BCTX or PMN?

Promis Neurosciences is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Briacell Therap N/A N/A -$26.31M -$7.92 N/A Promis Neurosciences N/A N/A -$39.72M -$14.51 N/A

Is BCTX or PMN more profitable?

Briacell Therap's return on equity of -153.53% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% Promis Neurosciences N/A -237.99% -151.04%

Which has higher earnings and valuation, PLYX or BCTX?

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polaryx Therapeutics N/A N/A N/A -$0.05 N/A Briacell Therap N/A N/A -$26.31M -$7.92 N/A

Is PLYX or BCTX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Briacell Therap N/A -153.53% -129.26%

Briacell Therap (BCTX) Competitors

$3.70 -0.05 (-1.33%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$3.85 +0.15 (+4.00%)

As of 07:07 AM Eastern

Compare

BCTX vs. ALDX, ENGN, SPRO, PMN, and PLYX

Should you buy Briacell Therap stock or one of its competitors? MarketBeat compares Briacell Therap with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Briacell Therap include Aldeyra Therapeutics (ALDX), enGene (ENGN), Spero Therapeutics (SPRO), Promis Neurosciences (PMN), and Polaryx Therapeutics (PLYX). These companies are all part of the "pharmaceutical products" industry.

How does Briacell Therap compare to Aldeyra Therapeutics?

Briacell Therap (NASDAQ:BCTX) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Aldeyra Therapeutics' return on equity of -57.34% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

Briacell Therap has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

Aldeyra Therapeutics has a consensus price target of $5.50, indicating a potential upside of 184.97%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Aldeyra Therapeutics had 1 more articles in the media than Briacell Therap. MarketBeat recorded 2 mentions for Aldeyra Therapeutics and 1 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.93 beat Aldeyra Therapeutics' score of 0.62 indicating that Briacell Therap is being referred to more favorably in the media.

Company	Overall Sentiment
Briacell Therap	Positive
Aldeyra Therapeutics	Positive

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 0.7% of Briacell Therap shares are held by insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Aldeyra Therapeutics beats Briacell Therap on 10 of the 13 factors compared between the two stocks.

How does Briacell Therap compare to enGene?

Briacell Therap (NASDAQ:BCTX) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Briacell Therap has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, enGene has a beta of -0.28, indicating that its share price is 128% less volatile than the broader market.

In the previous week, enGene had 3 more articles in the media than Briacell Therap. MarketBeat recorded 4 mentions for enGene and 1 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.93 beat enGene's score of 0.45 indicating that Briacell Therap is being referred to more favorably in the media.

Company	Overall Sentiment
Briacell Therap	Positive
enGene	Neutral

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 0.7% of Briacell Therap shares are held by insiders. Comparatively, 10.5% of enGene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

enGene's return on equity of -56.06% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
enGene	N/A	-56.06%	-45.64%

enGene is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
enGene	N/A	N/A	-$117.30M	-$2.17	N/A

enGene has a consensus price target of $11.05, indicating a potential upside of 482.87%. Given enGene's stronger consensus rating and higher probable upside, analysts plainly believe enGene is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

enGene beats Briacell Therap on 9 of the 13 factors compared between the two stocks.

How does Briacell Therap compare to Spero Therapeutics?

Briacell Therap (NASDAQ:BCTX) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Spero Therapeutics has higher revenue and earnings than Briacell Therap. Briacell Therap is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Spero Therapeutics	$66.80M	1.47	$8.57M	$0.24	7.08

Briacell Therap has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by insiders. Comparatively, 2.9% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Spero Therapeutics had 9 more articles in the media than Briacell Therap. MarketBeat recorded 10 mentions for Spero Therapeutics and 1 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.93 beat Spero Therapeutics' score of 0.55 indicating that Briacell Therap is being referred to more favorably in the media.

Company	Overall Sentiment
Briacell Therap	Positive
Spero Therapeutics	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Spero Therapeutics has a net margin of 24.90% compared to Briacell Therap's net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Spero Therapeutics	24.90%	35.58%	24.95%

Summary

Spero Therapeutics beats Briacell Therap on 12 of the 13 factors compared between the two stocks.

How does Briacell Therap compare to Promis Neurosciences?

Briacell Therap (NASDAQ:BCTX) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Briacell Therap's return on equity of -153.53% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Promis Neurosciences	N/A	-237.99%	-151.04%

Briacell Therap has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.23, indicating that its stock price is 123% less volatile than the broader market.

Promis Neurosciences is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

In the previous week, Promis Neurosciences had 6 more articles in the media than Briacell Therap. MarketBeat recorded 7 mentions for Promis Neurosciences and 1 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.93 beat Promis Neurosciences' score of 0.70 indicating that Briacell Therap is being referred to more favorably in the media.

Company	Overall Sentiment
Briacell Therap	Positive
Promis Neurosciences	Positive

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 0.7% of Briacell Therap shares are held by insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Promis Neurosciences has a consensus target price of $24.00, suggesting a potential upside of 75.70%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts clearly believe Promis Neurosciences is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Summary

Briacell Therap and Promis Neurosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Briacell Therap compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Briacell Therap (NASDAQ:BCTX) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

15.4% of Briacell Therap shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A

Polaryx Therapeutics' return on equity of 0.00% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Briacell Therap	N/A	-153.53%	-129.26%

Polaryx Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 276.11%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Polaryx Therapeutics is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Polaryx Therapeutics had 14 more articles in the media than Briacell Therap. MarketBeat recorded 15 mentions for Polaryx Therapeutics and 1 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.93 beat Polaryx Therapeutics' score of 0.85 indicating that Briacell Therap is being referred to more favorably in the news media.

Company	Overall Sentiment
Polaryx Therapeutics	Positive
Briacell Therap	Positive

Summary

Polaryx Therapeutics beats Briacell Therap on 7 of the 11 factors compared between the two stocks.

Get Briacell Therap News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCTX vs. The Competition

Export

Metric	Briacell Therap	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$32.62M	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-0.47	20.98	26.96	24.38
Price / Sales	N/A	311.10	518.38	91.92
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	0.40	8.54	10.90	6.33
Net Income	-$26.31M	$23.83M	$3.59B	$331.02M
7 Day Performance	N/A	-2.77%	-1.51%	-0.33%
1 Month Performance	35.04%	5.85%	2.76%	-1.29%
1 Year Performance	-51.95%	52.15%	28.54%	21.30%

Briacell Therap Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCTX Briacell Therap	0.5702 of 5 stars	$3.70 -1.3%	N/A	-81.7%	$32.62M	N/A	N/A	8
ALDX Aldeyra Therapeutics	3.7332 of 5 stars	$2.14 -4.3%	$5.50 +157.6%	-61.5%	$127.58M	N/A	N/A	10
ENGN enGene	3.8912 of 5 stars	$1.89 -1.8%	$11.05 +486.0%	-43.3%	$126.28M	N/A	N/A	31	Gap Down
SPRO Spero Therapeutics	1.0817 of 5 stars	$2.17 +0.2%	N/A	-35.6%	$125.06M	$66.80M	9.00	150	News Coverage
PMN Promis Neurosciences	4.0329 of 5 stars	$13.64 +0.7%	$24.00 +76.0%	+5.1%	$122.35M	N/A	N/A	5	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCTX) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Briacell Therap (BCTX) Competitors

BCTX vs. ALDX, ENGN, SPRO, PMN, and PLYX

How does Briacell Therap compare to Aldeyra Therapeutics?

Summary

How does Briacell Therap compare to enGene?

Summary

How does Briacell Therap compare to Spero Therapeutics?

Summary

How does Briacell Therap compare to Promis Neurosciences?

Summary

How does Briacell Therap compare to Polaryx Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCTX vs. The Competition

Briacell Therap Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Briacell Therap (BCTX) Competitors

BCTX vs. ALDX, ENGN, SPRO, PMN, and PLYX

How does Briacell Therap compare to Aldeyra Therapeutics?

Is BCTX or ALDX more profitable?

Which has better earnings and valuation, BCTX or ALDX?

Which has more volatility & risk, BCTX or ALDX?

Do analysts rate BCTX or ALDX?

Does the media prefer BCTX or ALDX?

Do insiders & institutionals hold more shares of BCTX or ALDX?

Summary

How does Briacell Therap compare to enGene?

Which has more volatility & risk, BCTX or ENGN?

Does the media prefer BCTX or ENGN?

Do institutionals and insiders have more ownership in BCTX or ENGN?

Is BCTX or ENGN more profitable?

Which has stronger earnings & valuation, BCTX or ENGN?

Do analysts prefer BCTX or ENGN?

Summary

How does Briacell Therap compare to Spero Therapeutics?

Which has better valuation and earnings, BCTX or SPRO?

Which has more volatility and risk, BCTX or SPRO?

Do institutionals & insiders hold more shares of BCTX or SPRO?

Does the media prefer BCTX or SPRO?

Do analysts prefer BCTX or SPRO?

Is BCTX or SPRO more profitable?

Summary

How does Briacell Therap compare to Promis Neurosciences?

Is BCTX or PMN more profitable?

Which has more risk and volatility, BCTX or PMN?

Which has better earnings & valuation, BCTX or PMN?

Does the media prefer BCTX or PMN?

Do institutionals & insiders hold more shares of BCTX or PMN?

Do analysts rate BCTX or PMN?

Summary

How does Briacell Therap compare to Polaryx Therapeutics?

Do institutionals & insiders have more ownership in PLYX or BCTX?

Which has higher earnings and valuation, PLYX or BCTX?

Is PLYX or BCTX more profitable?

Do analysts rate PLYX or BCTX?

Does the media prefer PLYX or BCTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCTX vs. The Competition

Briacell Therap Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools